Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yatharth Hospital & Trauma Care Services Limited (YATHARTH.NS)
Noida, IN
Established in 2008 and headquartered in Noida, India, Yatharth Hospital & Trauma Care Services Limited operates and manages super-specialty medical facilities across Delhi and Madhya Pradesh. These hospitals offer an extensive range of healthcare services. Core specializations include women's health (gynecology), digestive medicine (gastroenterology), respiratory conditions (pulmonology), pediatrics, kidney and urinary tract care (nephrology and urology), cardiology, orthopedics, spine and rheumatology, and neurosciences. Additionally, the company provides general medicine, surgery, ENT, physiotherapy, rehabilitation, interventional spine and pain medicine, nutrition, pathology, laboratory diagnostics, dentistry, ophthalmology, dermatology, anesthesiology, radiology, and psychology and psychiatry.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.83% | -1.26% | +14.24% | +17.73% | +6.28% | +20.29% | +56.15% | +145.78% | +145.78% | +145.78% | +145.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+37.1% ★ Q1'26: +47.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+23.6% ★ Q1'26: +8.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+10.1% ★ Q1'26: -43.5% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+16.9% ★ Q1'26: +14.6% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+8.6% ★ Q1'26: +9.5% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+12.8% Q1'26: +12.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.90× ★ Q1'26: 0.83× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
6.71B
est: 7.46B (-10.2%)
|
8.80B
est: 8.92B (-1.3%)
|
11.99B
11.98B – 12.01B
+34.4% YoY
|
16.14B
15.94B – 16.44B
+34.6% YoY
|
21.03B
20.83B – 21.23B
+30.3% YoY
|
| EBITDA |
1.96B
est: 2.09B (-6.5%)
|
2.36B
est: 2.50B (-5.4%)
|
3.36B
3.35B – 3.36B
+34.4% YoY
|
4.52B
4.46B – 4.61B
+34.6% YoY
|
5.89B
5.83B – 5.95B
+30.3% YoY
|
| EBIT |
1.66B
est: 1.61B (+3.1%)
|
1.79B
est: 1.93B (-7.0%)
|
2.59B
2.59B – 2.59B
+34.4% YoY
|
3.49B
3.44B – 3.55B
+34.6% YoY
|
4.54B
4.50B – 4.59B
+30.3% YoY
|
| Net Income |
1.14B
est: 1.26B (-9.0%)
|
1.31B
est: 1.25B (+4.7%)
|
1.73B
1.73B – 1.74B
+38.9% YoY
|
2.33B
2.12B – 2.71B
+34.6% YoY
|
3.08B
2.91B – 4.20B
+31.9% YoY
|
| SGA |
74.84M
est: 589.86M (-87.3%)
|
3.19B
est: 705.03M (+352.8%)
|
947.73M
946.50M – 948.96M
+34.4% YoY
|
1.28B
1.26B – 1.30B
+34.6% YoY
|
1.66B
1.65B – 1.68B
+30.3% YoY
|
| EPS |
14.46
est: 14.81 (-2.4%)
|
14.72
est: 14.55 (+1.2%)
|
20.29
20.24 – 20.34
+39.4% YoY
|
27.87
24.77 – 31.77
+37.4% YoY
|
39.13
34.07 – 49.14
+40.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck India Growth Leaders ETF GLIN | 0.19% | 182.8K | 0.72% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 234.4K | 0.65% |
| 3 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.00% | 85.7K | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ajay Kumar Tyagi | Chairman & Whole-time Director | 12M | male |
| Kapil Kumar Tyagi | MD & Director | 12M | — |
| Yatharth Tyagi | Whole-Time Director | 12M | male |
| Deepak Kumar Tyagi | President of Strategy and Finance | — | male |
| Sonu Goyal | Group Chief Financial Controller | — | male |
| Nitin Gupta | Group Chief Operating Officer & President of Finance | — | male |
| Pankaj Prabhakar | Chief Financial Officer | — | male |
| Ritesh Mishra | Company Secretary & Compliance Officer | — | male |
| Amit Kumar Singh | Group Chief Executive Officer | — | male |
| Ashutosh Kumar Jha | Group Chief Strategy, M&A and Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for YATHARTH.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
